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THBS2, identiﬁed in this genome-wide association study, is
expressed in mouse bile ducts, and the protein appears to
inhibit JAG1–NOTCH2 interactions. These data implicate
THBS2 as a candidate genetic modiﬁer of liver disease
severity in Alagille syndrome.
BACKGROUND & AIMS: Alagille syndrome is an autosomal-
dominant, multisystem disorder caused primarily by muta-
tions in JAG1, resulting in bile duct paucity, cholestasis, cardiac
disease, and other features. Liver disease severity in Alagille
syndrome is highly variable, however, factors inﬂuencing the
hepatic phenotype are unknown. We hypothesized that genetic
modiﬁers may contribute to the variable expressivity of this
disorder.
METHODS:We performed a genome-wide association study in a
cohort of Caucasian subjects with known pathogenic JAG1 mu-
tations, comparing patients with mild vs severe liver disease,
followed by functional characterization of a candidate locus.
RESULTS: We identiﬁed a locus that reached suggestive
genome-level signiﬁcance upstream of the thrombospondin 2
(THBS2) gene. THBS2 codes for a secreted matricellular protein
that regulates cell proliferation, apoptosis, and angiogenesis,
and has been shown to affect Notch signaling. By using a re-
porter mouse line, we detected thrombospondin 2 expression
in bile ducts and periportal regions of the mouse liver. Exam-
ination of Thbs2-null mouse livers showed increased micro-
vessels in the portal regions of adult mice. We also showed that
thrombospondin 2 interacts with NOTCH1 and NOTCH2 and
can inhibit JAG1–NOTCH2 interactions.
CONCLUSIONS: Based on the genome-wide association study
results, thrombospondin 2 localization within bile ducts, and
demonstration of interactions of thrombospondin 2 with JAG1
and NOTCH2, we propose that changes in thrombospondin 2
expression may further perturb JAG1–NOTCH2 signaling inpatients harboring a JAG1 mutation and lead to a more severe
liver phenotype. These results implicate THBS2 as a plausible
candidate genetic modiﬁer of liver disease severity in Alagille
syndrome. (Cell Mol Gastroenterol Hepatol 2016;2:663–675;
http://dx.doi.org/10.1016/j.jcmgh.2016.05.013)
Keywords: JAG1; NOTCH2; Gene Modiﬁer; Cholestasis; Genome-
Wide Association Study.
lagille syndrome (ALGS) is an autosomal-dominantAdisorder caused by mutations in the Notch
pathway ligand JAG1 in 94% of patients and in 1 of 4
Notch receptors (NOTCH2) in 1%–2%. ALGS is charac-
terized by bile duct paucity, cholestatic liver disease,
congenital heart lesions, eye and skeletal anomalies, and a
characteristic facial appearance. However, there is exten-
sive variation in the expressivity of the disease, and var-
iable penetrance of clinical features in ALGS patients has
been observed since the earliest description of the syn-
drome.1 Before mutations in JAG1 were found to be the
principal cause of ALGS, examination of inherited cases
showed extreme phenotypic variability, even among
family members.2-4 We suspect that this phenotypic
Table 1.Stratiﬁcation of Liver Disease Severity
Liver disease
severity Clinical features
Mild 1. No known hepatic involvement; normal liver
test results
2. Biochemical abnormalities (serum amino-
transferase levels greater than the upper
limit of normal for the laboratory, but not
normal bilirubin)
3. Biochemical cholestasis without overt clin-
ical manifestations: increased conjugated
bilirubin (>15% of total bilirubin or >2 mg/
dL) or increased cholesterol, bile salts, or g-
glutamyltransferase levels above the upper
limit of normal for the laboratory
Severe Cholestasis (as described earlier) with clinical
manifestations including severe pruritus,
xanthomata, bone fractures
Excluded Any of the following
Died when younger than age of 5
Liver transplant when younger than age of 5
Biliary diversion when younger than age of 5
History of Kasai procedure
Not enough clinical data or currently younger
than age 5
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with genetic modiﬁers.
The liver disease seen in ALGS patients is highly var-
iable, ranging from subclinical to severe, and factors
inﬂuencing the hepatic phenotype are unknown. Unlike
the cardiac defects, in which severe forms of cardiac
disease can be categorized at initial presentation, liver
disease severity cannot be predicted based on the pres-
ence of bile duct paucity alone. Early symptoms may
resolve and never develop into severe liver disease,
however 20%–30% of ALGS patients eventually will
require liver transplantation.5–8 It also has been observed
that liver disease in children younger than 5 years of age
is not a stable predictor of long-term need for liver
transplantation,9 although more recent work has shown
that the combinatorial quantiﬁcation of serum total bili-
rubin, liver biopsy ﬁbrosis, and the presence of xantho-
mata is predictive of long-term hepatic disease, offering a
prognostic metric for this phenotype.10 No environmental
factor inﬂuencing liver disease severity has been identi-
ﬁed to date. Attempts to establish a genotype–phenotype
correlation between JAG1 mutations and the liver
phenotype have been unable to substantiate any con-
nection,11–14 and there presently is no reliable genetic
biomarker that is able to explain the high degree of liver
disease variability seen in ALGS. We hypothesize that
genetic modifying factors contribute to this phenotype,
such that some children will progress to end-stage liver
disease because of their genetic risk.
We designed a genome-wide association study (GWAS)
to identify loci that inﬂuence liver disease severity in ALGS
patients. The strongest association was found in the
genomic region upstream of the gene encoding thrombo-
spondin 2, a matricellular protein known to interact with
the Notch signaling pathway.Materials and Methods
Sample Cohort and Stratiﬁcation
ALGS patients who were positive for a JAG1 mutation
were enrolled in the study either through the Children’s
Hospital of Philadelphia or through the Longitudinal Study
of Genetic Causes of Intrahepatic Cholestasis protocol within
the Childhood Liver Disease Research Network (ChiLDReN),
a National Institute of Diabetes and Digestive and Kidney
Diseases/National Institutes of Health–funded network of
16 pediatric academic medical centers across North Amer-
ica. This study was approved by the Institutional Review
Boards at each center and informed consent was obtained
from parents/guardians or subjects 18 years or older. Data
from all patients were reviewed to determine liver disease
severity, using a stratiﬁcation protocol based on a combi-
nation of clinical and biochemical ﬁndings (Table 1). At the
time of enrollment in this study, there was no reliable
predictor of outcome before age 5, therefore stratiﬁcation
was limited to ALGS patients older than 5 years of age.9 The
2 cohorts, mild and severe, showed no correlation in JAG1
mutation type, as has been reported previously
(Supplementary Table 1).11–14Genotyping and Quality Control
There were 234 patients genotyped on the Omni1 (n ¼
138) and the OmniExpress (n ¼ 96) single-nucleotide
polymorphism (SNP) arrays (Illumina, San Diego, CA). Ge-
notype data from both platforms were merged into 1 data
set, keeping the 705,132 markers present on both arrays.
We followed standard quality control procedures to select
samples and SNPs for the association test. SNPs with a
minor allele frequency less than 0.05, a missing rate greater
than 0.05, or not in Hardy–Weinberg equilibrium (Phwe <
.00001) were removed. The remaining 579,677 SNP
markers were tested for association. Samples with a missing
rate greater than 0.05 also were removed. The X chromo-
some heterozygosity rate also was used as a quality control
metric and did not show any inconsistency between re-
ported sex and genotype data.
Individuals of European ancestry accounted for the
largest ethnic group in our cohort, and only these samples
were used to mitigate biases that may arise from population
stratiﬁcation. European ancestry was inferred by multidi-
mensional scaling with PLINK software.15 Multidimensional
scaling was performed on our samples and a HapMap data
set of 4 populations: Utah residents with northern and
western Europe ancestry; Han Chinese in Beijing, China;
Japanese in Tokyo, Japan; and Yoruba in Ibadan, Nigeria16
(Supplementary Figure 1). From the ﬁrst 2 multidimen-
sional scaling components, C1 and C2, patients with -0.0525
< C1 < -0.04 and -0.04 < C2 < -0.03 were selected as our
cohort with European ancestry based on visual inspection.
To identify identical and related individuals, we esti-
mated identity-by-state by genome-wide pairwise compar-
isons among all patients. We found 11 samples that were
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phia cohort and once in ChiLDReN. There were 3 pairs of
monozygotic twins with concordant liver phenotype,
therefore only 1 proband from each pair was included in
subsequent analysis. The remaining pairs with p greater
than 0.15 (indicating relatedness) were accounted for by
our knowledge of their relationships, except for 1 pair. We
suspect that in this pair the de-identiﬁed ChiLDReN proband
was the child of the subject who was enrolled in the Chil-
dren’s Hospital of Philadelphia cohort. Because of the small
number of enrolled families (n ¼ 19), it was not possible to
correlate risk allele with severity among relatives.
SNP Association Analysis
After sample quality control including controlling for
population stratiﬁcation and excluding repeated samples, 97
mild and 64 severe liver disease subjects remained for
analysis. Because relatives were included in our data set, we
used EMMAX, an implementation of the variance component
approach that accounts for sample structure,17 to test for
association. Suggestive evidence for association was
considered if SNPs reached the threshold of 1  10-5, which
yields approximately 1 false-positive association per GWAS
in populations of European ancestry.18
For a ﬁner resolution of the candidate regions, we per-
formed imputation with IMPUTE2, using the recommended
settings.19 Reference haplotypes were provided from the
1000 Genomes phase I data set.20 Following these recom-
mendations, SNPs with imputation quality score INFO less
than 0.8 and minor allele frequency less than 0.05 were
removed from subsequent analysis. The imputed data set
was analyzed by SNPTEST using an additive linear model.19
Mouse Lines
Thrombospondin 2 (Thbs2)-null mice have been
described previously.21 Thbs2–green ﬂuorescent protein
(GFP) reporter mice expressing GFP driven by the Thbs2
promoter were produced by the Gene Expression Nervous
System Atlas program using a bacterial artiﬁcial chromo-
some clone spanning 70 kb upstream to 75 kb downstream
of the Thbs2 gene as previously described.22 Genotyping for
all mice was performed by polymerase chain reaction (PCR)
analysis using genomic DNA isolated from the tail tip. All
procedures involving mice were conducted in accordance
with federal guidelines and approved Institutional Animal
Care and Use Committee protocols. All animals received
humane care according to the criteria outlined in the
Guidelines for the Care and Use of Laboratory Animals.
Immunohistochemistry and Immunoﬂuorescence
Standard protocols for immunohistochemistry and
immunoﬂuorescence were used on liver tissues from
Thbs2–GFP reporter, Thbs2-null, and control mice. Further
technical information including ﬁxation, antibodies used,
and antigen retrieval and blocking can be found in
Supplementary Table 2. Slides were scanned using the
Aperio Scan Scope OS at 20 (Leica Microsystems, Buffalo
Grove, IL) for immunohistochemistry and were mounted forviewing with the Olympus BX-51 ﬂuorescent microscope
(Olympus, Center Valley, PA) for immunoﬂuorescence.
Laser Capture Microdissection and
Complementary DNA Ampliﬁcation
Two 1-week-old C57BL/6J mouse livers were snap frozen
in optimal cutting temperature compound (Sakura Finetak,
USA, Inc, Torrance, CA). Each liver was sectioned at 12-mm
thickness under RNAse-free conditions and placed on a
polyethylene teraphthalate (PET)-membrane framed slide
for laser capture microdissection (ASEE Products, Knoxville,
TN). Sections were ﬁxed in a brief dehydration with ethanol
and xylene using standard protocols. Portal tracts were
identiﬁed under 10 objective light microscopy using the
Nikon Eclipse TE2000-S microscope (Nikon Instruments,
Melville, NY) and approximately 12–20 portal tracts were
selected and cut using mmiCellTools v2.3 software equipped
with a solid-state UV laser (Molecular Machines and In-
dustries, Eching, Germany). The remaining tissue on each
section was extracted (liver lobule) to serve as a control and
was considered to be enriched for parenchymal transcripts.
Samples were collected using PCR sample tubes for laser
capture microdissection (ASEE Products). Extraction buffer
was applied to samples and they were placed on dry ice until
RNA isolation using the PicoPure RNA isolation kit (Life
Technologies, Grand Island, NY).
The Ovation Pico WTA System V2 kit was used to pro-
duce approximately 10–20 mg of single primer isothermal
ampliﬁcation complementary DNA (cDNA) from approxi-
mately 15–25 ng of total RNA (NuGEN Technologies, San
Carlos, CA) following their standard protocol. RNA integrity
and purity was conﬁrmed before cDNA synthesis using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc, Wil-
mington, DE) and a NanoDrop (Wilmington, DE). Ampliﬁed
products were puriﬁed a second time using Qiagen’s
(Germantown, MD) QIAquick PCR puriﬁcation kit and cDNA
yield and purity was assessed again via both a NanoDrop as
well as an Agilent DNA 1000 Bioanalyzer.
Gene Expression Analysis
Droplet digital PCR (ddPCR) was performed on a Bio-
Rad QX100 ddPCR system (Hercules, CA) using cDNA har-
vested from laser capture microdissected tissue kindly
provided to us by Dr Matthew Ryan (Division of Gastroen-
terology, Hepatology, and Nutrition, Children’s Hospital of
Philadelphia). Droplets containing 60 ng of cDNA from
mouse portal tracts were created using TaqMan (Thermo
Fisher Scientiﬁc, Waltham, MA) mouse Thbs2 primer and
probe set (Mm01279240_m1) with TaqMan primer and
probe set for the control gene, Tbp (Mm00446971_m1).
Standard ddPCR methods were used for experimental con-
ditions and subsequent analysis.23
Microvessel, Biliary, and Arterial Counts
Average numbers of microvessels (CD34þ) and mature
bile ducts (cytokeratin 19 [CK19]þ) per portal tract were
calculated based on examination of 4 Thbs2-null and 4 con-
trol 1-week-old and adult livers using immunoﬂuorescence.
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and portal areas were outlined. Microvessels positively
expressing CD34 and mature bile ducts positively expressing
CK19 with a visible lumen within the designated portal re-
gion were counted and averages were calculated. For arterial
counts, immunohistochemistry was performed on parafﬁn-
embedded sections using CK19 and smooth muscle actin
antibodies. Four 1-week-old Thbs2-null and control livers
and 5 adult Thbs2-null and control livers were examined. The
number of arteries were counted across entire liver sections
and quantiﬁed by determining the average number of
arteries per mm2. Results of the microvessel and arterial
counts are presented as means and SEMs. Data were
analyzed using the unpaired t test with a 2-tailed P value for
statistical signiﬁcance.
Co-immunoprecipitation
The 293A cells plated on 6-well plates were transfected
with expression constructs encoding proteins of interest for
48 hours. The immunoprecipitation protocol has been
described previously.24 Plasmids encoding the ectodomains
of NOTCH1 and NOTCH2 fused to a C-terminal V5 epitope
tag have been described.25
Retrovirus Production and Transduction
Phoenix A (amphotropic) cells were plated at a density
of 4  105 cells/well on a 6-well plate. On the following day,
culture media was replaced with fresh media (Dulbecco’s
modiﬁed Eagle medium, high glucose, 10% fetal bovine
serum, pen-strep, L-glutamine). Chloroquine dihydro-
chloride (S764663; Sigma, St. Louis, MO) was added to
Phoenix cells 5 minutes before transfection and 2 mg of
plasmid DNA was transfected into cells using the Profection
kit (E1200; Promega, Madison, WI). The media was changed
10 hours after transfection. Retroviral supernatant was
collected the following day and 2 mL was added to GPþE86
cells, plated at 4  104 cells/well on a 6-well dish the
previous day, after ﬁltration (0.45 mm) and supplemented
with protamine sulfate (5 mg/mL). GPþE86 cells were
transduced again on the following day. Viral supernatant
from GPþE86 cells was collected on the following 2 days
and used to transduce C3H10T1/2 cells.
Binding Assays
Recombinant proteins from R&D Systems (Minneapolis,
MN) in this study include the following: recombinant human
NOTCH2-Fc and NOTCH3-Fc fusions (containing the ﬁrst 11
epidermal growth factor-like repeats), rat JAG1-Fc, human
full-length thrombospondin 2, and control human IgG1 Fc.
For protein labeling, 5 mg of protein was incubated with
Alexa700-succinimide (10 mg) in phosphate-buffered saline
at room temperature for 1 hour. Unincorporated label was
removed using a size exclusion column equilibrated in Tris
buffer (25-kilodalton cut-off level; Bio-Rad). Labeling of
proteins was veriﬁed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis under reducing condi-
tions, followed by visualization of label using a LI-COR
Odyssey ﬂatbed infrared detector (LI-COR Biosciences,Lincoln, NE). All proteins were predominantly 1 band of the
expected molecular weight at an apparent purity of at least
90%. Target proteins were coated on 96-well, ﬂat-bottom
enzyme-linked immunosorbent assay plates at 5 mg/mL in
Tris-buffered saline (50 mmol/L Tris, 150 mmol/L NaCl)
with 2 mmol/L CaCl2 overnight at 4C and then blocked
with 1% bovine serum albumin (BSA) in Tris-buffered sa-
line with 2 mmol/L CaCl2 for 1 hour at room temperature.
The wells then were incubated with Alexa700-
succinimide–labeled proteins in Tris-buffered saline plus 2
mmol/L CaCl2 and 0.05% Tween 20 at 4C overnight. In
some experiments, unlabeled thrombospondin 2 was added
to the binding reaction to assess the effect on binary in-
teractions. Bound, labeled proteins were quantiﬁed with a
LI-COR Odyssey ﬂatbed infrared detector (LI-COR Bio-
sciences). Ligand binding studies of proteins immobilized on
plastic have been described previously.24 As in the previous
study, control studies of the labeled proteins used here
showed only trivial amounts of labeling of Fc and BSA
control-coated plates.Generation of Thrombospondin 2 Type I Repeat
Deletion Constructs
A retroviral construct missing all 3 type I repeat domains
(amino acids 379–549, THBS2-Del3) was generated by PCR
ampliﬁcation of a 1169-base pair fragment encoding amino
acids 1–378 (fragment 1) and a 1925-base pair fragment
encoding amino acids 550–1172 (fragment 2), followed by
cloning into the pCRII-TOPO vector (Invitrogen, Carlsbad,
CA). SfoI restriction sites were added to the 3’ primer of
fragment 1 and the 5’ primer of fragment 2 to allow for
ligation. Fragments 1 and 2 were released from pCRII-TOPO
using BamHI/SfoI and SfoI/XbaI, respectively, and ligated
into the pBluescript cloning vector. The full-length THBS2
and THBS2-Del3 fragment were released from pBluescript
using EcoRI and cloned into the pRET retroviral vector.Cell Culture
Stromal cells were harvested from femurs and tibias of
Thbs2-null and control mice and cultured as previously
described.26 At 80% conﬂuence, cells were trypsinized and
plated on 12-well tissue culture plates at a density of 1 
105 cells per well. Notch signaling was activated by pre-
coating tissue culture plates with 10 mg/mL of antibody
against the Fc portion of human IgG (Jackson ImmonoR-
esearch, West Grove, PA) for 1 hour and then incubating
with the indicated concentration of recombinant rat JAG1/
human Fc IgG chimeric protein (R&D Systems) for 2 hours
as previously described.27 For Notch reporter activity ex-
periments, Fc-JAG1 or TNF-related apoptosis-inducing
ligand (control) conditioned media28 were used to coat
plates instead of the recombinant Fc-JAG1 protein.RNA Extraction and Quantitative Reverse-
Transcription PCR
RNA was extracted using the RNeasy RNA extraction kit
(Qiagen, Venlo, The Netherlands) according to the
Figure 1. Genotyped and imputed
SNPs associated with liver disease
severity in ALGS patients. (A) Man-
hattan plot showing all genotyped
SNPs. X-axis: genomic coordinates
of GWAS tested SNPs from chro-
mosome 1 to X. Y-axis: signiﬁcance
level for each SNP on a -log10 scale.
Genome-level signiﬁcance, P ¼ 5 
10-8; suggestive P value threshold,
P ¼ 1  10-5. (B) Regional association
plot of 6q27. P values (left Y-axis)
obtained from an additive linear test
on the genotyped (circle, rs7382539)
and imputed (square, rs4078087 and
rs7451470) markers in the THBS2
genomic region (X-axis). The recom-
bination rate (right Y-axis) is calcu-
lated from the 1000 Genomes Phase I
data set of subjects with European
ancestry. The top 3 markers are in
strong linkage disequilibrium with
each other (r2 ¼ 1). (C) The top SNP
signal is shown with the proximal
THBS2 gene. The red arrow indicates
the site of the top signal from the SNP
association study. This region also is
marked by acetylated histone H3
lysine 27 (H3K27Ac) and mono-
methylated histone H3 lysine 4
(H3K4Me1) peaks. The solid blue bar
depicts the region of linkage
disequilibrium including SNP markers
with r2 > 0.2 with rs7382539.
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Figure 2. Expression of thrombospondin 2 in mouse portal tracts and bile ducts. (A) The adult Thbs2–GFP reporter (red)
mouse liver shows co-localization of thrombospondin 2 with the mature biliary marker CK19, (B) with broader expression seen
at 1 week of age. (C) A 1-week-old littermate control lacking the GFP reporter shows CK19 expression only. (D) ddPCR shows
that Thbs2 expression is increased by more than 5-fold in laser-captured portal tracts when compared with the remaining liver
lobule (N ¼ 2). No change in expression between the 2 tissue types is seen with the control gene, Tbp. (A–C) Antibodies
against GFP were used. Arrows indicate co-localization of (A and B) thrombospondin 2 and CK19 and (C) CK19 expression
alone. Images were obtained using the Aperio Scan Scope OS (Leica Microsystems) at 20. Scale bar: 25 mm. DAPI, 40,6-
diamidino-2-phenylindole.
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reverse-transcribed. Quantitative real-time PCR reactions
using SybrGreen I were performed on an ABI 7500 Fast
Real-Time PCR System (Life Technologies, Carlsbad, CA).
Relative changes in gene expression were determined by the
2DDCT method using b-actin as an endogenous control.
Transient Transfection and CSL-Luciferase Assay
C3H10T1/2 cells were plated on 12-well plates coated
with either Fc-Trail or Fc-JAG1 recombinant protein. After
36 hours, cells were co-transfected with 0.5 mg of CSL-
luciferase, a synthetic DNA construct in which 4 tandem
repeats of CBF-1, Suppressor of Hairless, Lag-1 binding el-
ements drive expression of ﬁreﬂy luciferase, and 100 ng of
pRL-TK, a constitutively active TK promoter driving
expression of renilla luciferase activity, using Lipofectamine
and Plus reagent (Invitrogen). Cells were harvested 48
hours after transfection and ﬁreﬂy and renilla luciferase
activities were measured using the Dual Luciferase assay kit
(Promega).
Immunoblotting
Protein was extracted from cultured human ﬁbroblast
samples using RIPA buffer (Sigma-Aldrich, St. Louis, MO)supplemented with proteinase inhibitors (Thermo Fisher
Scientiﬁc). All Western blots were run using NuPAGE
Tris-acetate pre-cast gels (Thermo Fisher Scientiﬁc). Mem-
branes were blocked with 5% milk and 2% BSA and incu-
bated for either 1 (b-actin, 1:5000) or 2 (thrombospondin 2,
1:50) nights with primary antibody. Membranes were
incubated in horseradish-peroxidase–conjugated secondary
antibody for 1 hour at room temperature and subsequently
were developed using Pierce ECL Western Blotting Sub-
strate (Thermo Fisher Scientiﬁc). Antibodies used included
thrombospondin 2 (BD Biosciences, San Jose, CA) and b-
actin (Millipore, Billerica, MA). Thrombospondin 2 expres-
sion was quantiﬁed and normalized to b-actin using ImageJ
software (National Institutes of Health, Bethesda, MD).
Results
SNP Association Analysis
We performed a GWAS to identify common genetic
variants inﬂuencing the severity of the hepatic phenotype in
ALGS. Although we did not observe any inﬂation in the Q-Q
plot of the observed against the expected P values (l ¼
1.005), indicating the quality control and analysis methods
correctly accounted for any potential population stratiﬁca-
tion (Supplementary Figure 2), none of the markers passed
Figure 3. Thrombospondin 2 is expressed in periportal mesenchyme and hepatocytes in mouse liver at 1 week of age.
(A–C) Thrombospondin 2 (GFP-green) co-localizes with the mesenchymal marker smooth muscle 22a (SM22a). (D–F)
Thrombospondin 2 (GFP-red) rarely is expressed in periportal hepatocytes (hepatocyte nuclear factor 4 a [HNF4a], arrows).
Bile ducts are labeled with CK19. Antibodies against GFP were used. Arrows indicate colocalization of GFP and HNF4a.
Images were obtained using the Aperio Scan Scope OS (Leica Microsystems) at 20. Scale bar: 25 mm.
September 2016 THBS2 and Alagille Syndrome 669the threshold for genome-wide signiﬁcance (P < 5  10-8).
However, 1 marker in 6q27 (rs7382539; P ¼ 1.8  10-6)
and 2 markers in 9q33.2 (rs944961; P ¼ 2.3  10-6; and
rs2900162; P ¼ 8.5  10-6) reached the suggestive P value
threshold (P < 1  10-5) (Figure 1A).
The most signiﬁcant marker, rs7382539, was located at
6q27, 14-kb upstream of THBS2. This marker is in moderate
linkage disequilibrium (r2 > 0.2) with SNPs up to approxi-
mately 2 kb upstream of THBS2 in the 1000 Genomes
European superpopulation (Figure 1C). After imputation, 2
additional SNPs, rs4078087 and rs7451470, showed the
same magnitude of signiﬁcance as rs7382539 (Figure 1B).
These 3 SNPs are correlated strongly with each otherFigure 4. Normal bile
ducts in Thbs2-null
mouse liver. Immunoﬂuo-
rescence staining for bile
duct marker CK19 and
mesenchymal marker
smooth muscle 22a
(SM22a) shows normal bile
duct structures in the por-
tal tracts of (A) control and
(B) Thbs2-null mouse livers
at 1 week of age. Scale
bar: 25 mm. DAPI, 40,6-
diamidino-2-phenylindole.(r2 ¼ 1). Upon inspection of the Encyclopedia of DNA Ele-
ments histone modiﬁcation peaks in this marker region,29
we observed histone marks that may be indicative of
enhancer activity for both acetylated histone H3 lysine 27
and monomethylated histone H3 lysine 4 (Figure 1C).30
The second and third ranking markers were located on
9q33.2, almost 500 kb away from the nearest ﬂanking
genes, deleted in bladder cancer protein 1 (DBC1) and CDK5
regulatory subunit-associated protein 2 (CDK5RAP2). The
linkage disequilibrium block around these markers does not
include these genes. The region tagged by these markers did
not have any histone modiﬁcation peaks and was not in any
DNase I hypersensitivity clusters.29 Imputed SNPs did not
Table 2.Average Number of Microvessels and Bile Ducts per Portal Tract in 1-Week-Old and Adult Control and
Thbs2-Null Livers
Age Genotype Average microvessels, n P value Average bile ducts, n P value
1 week Thbs2-null 7.6 ± 0.5 .680 1.9 ± 0.2 1.000
Control 8.0 ± 0.7 1.9 ± 0.2
Adult Thbs2-null 12.1 ± 0.7 .001 2.3 ± 0.2 .460
Control 9.1 ± 0.5 2.1 ± 0.2
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these were not analyzed further.
Thrombospondin 2 Is Expressed in Biliary
Epithelium and Portal Regions of the Mouse Liver
Although our GWAS did not identify any markers that
reached genome-wide signiﬁcance, we were intrigued to
investigate the functional role of thrombospondin 2 given
the known interaction of thrombospondin 2 with Notch
proteins24 and the fundamental importance of Notch
signaling in ALGS. As a ﬁrst step toward interpreting the
potential signiﬁcance of the signal near THBS2, we analyzed
the expression pattern of thrombospondin 2 in the liver.
This was performed using a reporter mouse line expressing
GFP driven by the Thbs2 promoter (Thbs2-GFP). Examina-
tion of adult mouse livers showed co-localization of biliary
marker CK19 with GFP, indicating that thrombospondin 2 is
expressed in bile ducts (Figure 2A, arrow). Thrombospondin
2 expression in the adult mouse liver was conﬁned to the
periportal regions with no parenchymal expression. One-
week-old Thbs2–GFP reporter livers also were examined.
Again, CK19 co-localized with GFP, indicating thrombo-
spondin 2 expression in biliary epithelium (Figure 2B,
arrows). Of notable difference at the earlier time point is the
broader expression of thrombospondin 2 surrounding the
portal tracts, appearing to include mesenchymal cells and
periportal hepatocytes (Figure 3). Staining in control lit-
termates was negative for GFP, as expected (Figure 2C).
To conﬁrm these results, we examined expression levels
of Thbs2 messenger RNA transcripts in laser-captured
mouse portal tracts vs the remainder of the liver lobule
using ddPCR. cDNA ampliﬁed from control livers at 2
weeks of age showed greater than a 5-fold increase in
Thbs2 expression in the portal tracts vs the liver lobule
(Figure 2D). Thus, examination of Thbs2 messenger RNA
expression and thrombospondin 2 protein localization
using a GFP reporter mouse conﬁrm enrichment of
thrombospondin 2 in portal regions, with speciﬁc expres-
sion in biliary epithelium, mesenchyme, and, rarely, in
hepatocytes.Table 3.Average Number of Arteries in 1-Week-Old and Adult
Age Genotype Average arteries, n
1 week Thbs2-null 10.5 ± 1.4
Control 4.5 ± 0.9
Adult Thbs2-null 23.8 ± 2.5
Control 33.2 ± 3.4Thbs2-Null Mice Have Increased Microvessels in
Portal Regions
We examined Thbs2-null mouse livers at 12 weeks of
age and compared them with littermate controls. Liver
histology was unremarkable by H&E staining, and Sirius
red staining did not show ﬁbrosis in the mutant livers (data
not shown). Immunoﬂuorescence staining for CK19 showed
normal numbers and structure of bile ducts in the Thbs2-
null mice (Figure 4). Thbs2-null animals show increased
vascularity in different tissues including the eye,31,32
brain,33 skin,21 heart,34 and bone.35 We examined Thbs2-
null and littermate control livers at 1 and 12 weeks of age
using CK19 and CD34 antibodies to estimate the average
number of bile ducts and microvessels per portal tract
(Table 2). The average number of bile ducts was approxi-
mately 2 per portal tract in the Thbs2-null and control
livers at both time points. However, we identiﬁed a higher
average number of microvessels per portal tract in adult
Thbs2-null livers over littermate controls, expanding upon
the already reported phenotype of increased vascularity
seen in other Thbs2-null tissues. To reﬁne our assessment,
we calculated the size of each portal tract and veriﬁed that
areas examined among mutant and control portal tracts
were similar (data not shown). This difference in the
number of microvessels per portal tract was not seen in the
younger cohort.
In addition, we stained Thbs2-null and littermate con-
trol livers with smooth muscle actin to identify mature
arteries in portal tracts at 1 and 12 weeks of age. Inter-
estingly, we identiﬁed more arteries in the 1-week-old
Thbs2-null livers compared with controls, with approxi-
mately 10.5 arteries in the nulls and 4.5 in controls
(Table 3). Taking into account the area of each liver sec-
tion, the increase in the number of arteries per mm2 was
statistically signiﬁcant (P ¼ .01). Curiously, the opposite
was found in the adult liver, in which Thbs2-null livers had,
on average, 23.8 arteries, whereas controls showed 33.2
arteries (P ¼ .05). After normalization by area, the
numbers followed the same trend, but they were no longer
signiﬁcant (P ¼ .14).Control and Thbs2-Null Liver Sections
P value Average arteries, n, mmol/L2 P value
.010 3.7  10-7 .010
1.7  10-7
.050 2.7  10-7 .140
3.6  10-7
Figure 5. Thrombospondin 2 interacts with Notch in vitro.
(A) Immunoprecipitation of NOTCH1–V5, NOTCH2–V5, and
thrombospondin 2 with indicated antibodies. (B) Solid phase
binding assay to test the ability of thrombospondin 2 to inhibit
the interaction of the JAG1 ectodomain with NOTCH2. (C)
Competitive binding assay incubating increasing concentra-
tions of unlabeled thrombospondin 2 in NOTCH2 or NOTCH3
ectodomain-coated wells with a ﬁxed concentration of JAG1
ectodomain.
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Interactions In Vitro
Given the crucial role of JAG1–NOTCH2 interactions in
bile duct development, we performed in vitro binding assays
using puriﬁed proteins to determine the effect of throm-
bospondin 2 on JAG1–NOTCH2 binding. We found that
thrombospondin 2 can be isolated from protein complexes
containing either NOTCH1 or NOTCH2 ectodomains
(Figure 5A). We further found that when the JAG1 ectodo-
main is labeled and incubated on NOTCH2 ectodomain-
coated wells, addition of thrombospondin 2, but not BSA,
is able to strongly inhibit JAG1–NOTCH2 binding
(Figure 5B). In addition, increasing concentrations of
thrombospondin 2 inhibited formation of complexes that
included JAG1 and NOTCH2 (Figure 5C). Interestingly,
thrombospondin 2 enhances formation of complexes that
include JAG1 and NOTCH3 binding in this same assay
(Figure 5C). These results indicate that thrombospondin 2 is
able to interact directly with Notch proteins and interfere
with JAG1–NOTCH2 complex formation.
To determine the effects of thrombospondin 2 on Notch
pathway signaling, we assayed downstream gene expression
using stromal cells harvested from Thbs2-null mice and
exposed to JAG1 protein. We found that Notch pathway
target genes were markedly upregulated in the Thbs2-null
cells in a dose-dependent manner after exposure to JAG1
(Figure 6A). The most profound difference in both expres-
sion and JAG1 dose response between Thbs2-null and control
stromal cells occurred with Hey-L expression (Figure 6A).
Conversely, overexpression of thrombospondin 2 in vitro
resulted in reduced Notch pathway activation with at least
50% reduced expression of Hey1 compared with controls
(Figure 6B). Overexpression of a modiﬁed thrombospondin 2
construct lacking the type I repeat domain (THBS2-Del3) did
not reduce Hey1 expression as compared with control after
exposure to JAG1 (Figure 7). A Notch luciferase reporter
assay also showed a decrease in luciferase activity after
overexpression of the full-length thrombospondin 2 protein,
conﬁrming that thrombospondin 2 inhibits canonical Notch
signaling in this model (Figure 6C).
We attempted to investigate whether the risk allele
identiﬁed in the GWAS affected thrombospondin 2 RNA or
protein expression. Thrombospondin 2 is not expressed in
lymphoblastoid cell lines, so we studied ﬁbroblast cell lines
derived from ALGS and control individuals of different ge-
notypes. In control ﬁbroblast cell lines, we identiﬁed a trend
toward increased thrombospondin 2 protein expression in
individuals heterozygous (AG; mean fold difference over
control, 5.72; n ¼ 5) and homozygous (AA; mean fold dif-
ference over control, 7.65; n ¼ 2) for the risk allele
compared with those homozygous for the nonrisk allele (GG;
mean fold difference over control, 2.10; n ¼ 3), which would
support our hypothesis (Figure 8A). In the ALGS ﬁbroblast
samples, thrombospondin 2 protein expression was
extremely variable and there was no clear evidence of cor-
relation between genotype (AA; n ¼ 2) and expression level
(Figure 8B). Thrombospondin 2 RNA expression also
showed no correlation between genotype and expressionlevel (data not shown). We are cautious about interpreting
these ﬁndings both owing to the very low sample size we
had for both populations and the tissue type examined.
Ideally, we would like to study this type of correlation in
liver tissue, but it was not available to us at this time.
Further studies will be required to determine whether the
GWAS-identiﬁed SNP directly or indirectly regulates THBS2
expression, and if this effect is tissue speciﬁc.
Figure 6. Thbs2 expression alters Notch target gene expression. (A) Gene expression analysis by quantitative PCR of
Thbs2-null stromal cells shows up regulation of 3 Notch target genes in response to varying doses of JAG1 recombinant
protein. (B) Gene expression analysis by quantitative PCR shows reduced Hey1 messenger RNA (mRNA) expression when
C3H10T1/2 cells are transfected with a retrovirus expressing thrombospondin 2 relative to GFP. (C) A luciferase assay
measuring Notch activity shows that luciferase activity normalized to pRL-TK was decreased in thrombospondin
2–overexpressing cells relative to GFP-overexpressing cells.
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Our study has identiﬁed THBS2 as a compelling candi-
date modiﬁer gene of liver disease severity in ALGS.
Thrombospondin 2 is a matricellular protein that previously
was shown to potentiate JAG1–NOTCH3 interactions—a
function that is speciﬁc to thrombospondin 2 and not other
thrombospondin family members.24 Although thrombo-
spondin 2 has been studied in other tissues and found to be
associated with anti-angiogenic effects during wound heal-
ing,36 its role in the liver has not been studied to date. Given
the importance of both the JAG1 gene and Notch signaling in
the etiology of ALGS, we pursued additional functional
studies after identifying this gene through our GWAS. We
further show that thrombospondin 2 interacts with NOTCH1
and NOTCH2, and that increased concentration of throm-
bospondin 2 results in reduced binding of the
JAG1–NOTCH2 ligand-receptor pair. We also show that
thrombospondin 2 is expressed speciﬁcally in the biliary
epithelium and portal tracts of mouse liver (Figure 2).
Together these data are highly suggestive of a role for
thrombospondin 2 in the liver phenotype of ALGS.
Through the GWAS, we identiﬁed a SNP, rs7382539,
located 14 kb upstream of THBS2 on 6q27, that is associatedwith liver disease severity in ALGS patients with a JAG1
mutation. Although rs7382539 did not pass the cut-off for
genome-wide signiﬁcance, it did reach a suggestive level of
signiﬁcance for European populations. We identiﬁed 2
additional SNPs, rs4078087 and rs7451470, in strong
linkage disequilibrium with each other and with rs7382539
(r2 ¼ 1) and highly associated with liver disease severity
through imputation (Figure 1). These 3 SNPs are located in
regions with histone marks that are indicative of enhancer
activity, including acetylated histone H3 lysine 27 and
monomethylated histone H3 lysine 4.30 This suggests that
although the causal marker may not be in the coding
sequence of THBS2, it still potentially can play a role in
regulating this gene.
By using a reporter mouse, we identiﬁed a pattern of
expression for thrombospondin 2 in the portal tracts and
biliary epithelium of the adult liver (Figure 2) and showed
that this pattern extends into stromal cells and is seen rarely
in periportal hepatocytes in young mice (1 week old)
(Figure 3). Studies aiming to identify expression patterns of
thrombospondin 2 during murine embryogenesis found
high levels of expression in the heart, vessels, and mesen-
chyme.37 In addition, a role for thrombospondin 2 in
Figure 7. Type I repeats of THBS2 are required to inhibit Hey1 expression. (A) Schematic of the THBS2 gene showing type
I repeat domains. (B) Western blot showing thrombospondin 2 secretion into media by stably transduced C3H10T1/2 cells of
empty vector, thrombospondin 2 in which all 3 type I repeat domains have been deleted (THBS2-Del3), and full-length
thrombospondin 2 protein (FL-THBS2). (C) Empty vector–, FL-THBS2–, or THBS2-Del3–transduced cells were plated on
either Fc-control– (Fc) or recombinant JAG1-coated plates and Hey-1 mRNA expression was analyzed 4 days later. EGF,
epidermal growth factor; PC, procollagen.
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types.21, 31–35 A recent report identiﬁed a thinning of peri-
portal vascular smooth muscle cells in mice hap-
loinsufﬁcient for Jag1, suggesting that an angiogenic effect
associated with Notch signaling also is seen in the liver.38
We investigated a role for thrombospondin 2 in liver
vasculature and found that adult mice lacking thrombo-
spondin 2 had increased numbers of microvessels per portal
tract whereas 1-week-old mice, but not adult mice, showed
an increase in the number of arteries per portal tract
(Tables 2 and 3). This ﬁnding is in keeping with the results
of Krady et al,39 who found an increase in baseline arte-
riogenesis in Thbs2-null animals in an induced-ischemia
model of the hindlimb. Our ﬁnding within the 1-week-old
livers raises the possibility that the rate at which arteries
develop may be increased in the Thbs2-null livers, but that
once maturity is reached, the number of arteries either
normalizes or is reduced slightly. Our results both sub-
stantiate our expression data and suggest that thrombo-
spondin 2 may have combined roles in biliary development
and liver vasculature. In addition, they suggest that it may
be interesting to investigate thrombospondin 2 as a modi-
ﬁer of the heart and vascular phenotypes in ALGS. Indeed,
recent studies have found an association of THBS2 with a
variety of heart conditions, including coronary artery dis-
ease,40,41 thoracic aortic dissection,42 and heart failure with
preserved ejection fraction.43
Biologically, THBS2 represents an intriguing putative
modiﬁer of ALGS liver disease severity because it
previously has been shown in binding assays thatthrombospondin 2 is capable of physically binding to
NOTCH3 and JAG1.24 Here, we extended these observa-
tions and show that thrombospondin 2 also interacts with
NOTCH2 (Figure 5) and inhibits the expression of
downstream Notch target genes in the presence of JAG1
(Figure 6). Moreover, we determined that a speciﬁc
THBS2 regulatory domain, the type I repeat, is required
for this function (Figure 7). Type I repeats are known to
be required for binding to CD36, a glycoprotein expressed
on platelets, and for the antiangiogenic function of
thrombospondin 2.44 Given the increased numbers of
microvessels and arteries in Thbs2-null adult and 1-week-
old mice, respectively, these data suggest that thrombo-
spondin 2 may function via Notch signaling in the liver
vasculature such that enhanced thrombospondin 2 levels
could decrease Notch signaling and impair angiogenesis
during liver development, thereby modifying the liver
phenotype in ALGS. The precise molecular mechanism of
how thrombospondin 2 blocks NOTCH2 function remains
to be determined. Further studies will be needed to
distinguish between competitive inhibition of
JAG1–NOTCH2 inhibition by thrombospondin 2 vs the
allosteric effect of thrombospondin 2 on one of the
binding partners.
We acknowledge that our study had several limitations.
First, because of the rarity of the syndrome, our patient
cohort was small and the marker identiﬁed in the GWAS at
6q27 did not reach genome-wide statistical signiﬁcance.
However, given the known interaction of thrombospondin 2
with JAG1/NOTCH3, we were interested in further pursuing
Figure 8. Thrombospondin 2 expression levels in human
ﬁbroblasts. (A) Thrombospondin 2 expression is higher in
control ﬁbroblasts that are heterozygous or homozygous for
the risk allele (AG or AA) compared with those homozygous
for the nonrisk allele (GG). (B) There is no correlation between
thrombospondin 2 expression and genotype in disease ﬁ-
broblasts. Densitometry measurements are shown below
each Thbs2 blot and were quantiﬁed in ImageJ by normal-
izing to actin.
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show a signiﬁcant correlation between SNP genotype and
THBS2 expression level. It is possible that the GWAS-
identiﬁed SNP, located upstream of the THBS2 locus in a
region with histone acetylation signatures, functions to
regulate THBS2 expression in a tissue-speciﬁc manner.
Investigation of this possibility is outside the scope of the
current study, but might include chromosome conformation
capture, more detailed analysis of patient liver samples, and
studies in animal models. Despite these limitations, we
believe that the expression data and functional studies
provide compelling evidence that thrombospondin 2 could
modulate JAG1–NOTCH2 interactions, thereby modifying
liver disease severity in ALGS.
Ultimately, these data provide genetic, expression, and
functional evidence to support a role for THBS2 as a mod-
iﬁer of liver disease severity in ALGS. These ﬁndings could
have signiﬁcant clinical applications when the current
treatment course of liver disease is unpredictable,9 and the
identiﬁcation of a genetic modiﬁer may help in identifying
patient populations that will require liver transplantation at
an earlier age.References
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Supplementary Table 1.Stratiﬁcation of JAG1 Mutation
Type by Liver Disease Severity in
GWAS Patients
Mutation type Mild, % Severe, %
Missense 21 14
Nonsense 31 31
Frameshift 31 38
Splice site alteration 7 9
Whole gene deletion 1 0
Partial gene deletion 3 3
Chromosome deletion 6 3
Partial gene duplication 0 2
Supplementary Table 2.List of Antibodies, Reagents, and Experimental Conditions for Immunohistochemistry and
Immunoﬂuorescence
Antibody Species Catalog number Manufacturer Working dilution
CD34 Rabbit sc-9095 Santa Cruz Biotech, Dallas, TX 1:100
CK19 Rat TROMAIII University of Iowa, Iowa City, IA 1:75
GFP Rabbit ab6556 Abcam, Cambridge, MA 1:500a
GFP-FITC Goat Ab6662 Abcam 1:400
HNF4a Goat sc-6556 Santa Cruz Biotech 1:40
SMA Rabbit ab5694 Abcam 1:200
SM22a Rabbit ab14106 Abcam 1:100
Cy2 anti-rat Donkey 712-225-153 Jackson ImmunoResearch, West Grove, PA 1:400
Dy488 anti-goat Donkey 705-545-147 Jackson ImmunoResearch 1:400
Cy3 anti-rabbit Donkey 711-165-152 Jackson ImmunoResearch 1:500
Biotinylated anti-rat IgG Rabbit BA-4001 Vector Laboratories, Burlingame, CA
Fix Antigen retrieval Block Secondary antibody
CD34 3% Formaldehyde -20C Methanol 2% milk/5% BSA Cy3-donkey anti-rabbit
CK19 3% Formaldehyde 0.25% Triton X-100 2% milk/5% BSA Cy2-donkey anti-rat
GFP 3% Formaldehyde 0.25% Triton X-100 2% milk/5% BSA Cy3-donkey anti-rabbit
GFP-FITC 3% Formaldehyde 0.25% Triton X-100 3% milk/10% BSA N/A
HNF4a 3% Formaldehyde 0.25% Triton X-100 3% milk/10% BSA Dy488-donkey anti-goat
SM22a 3% Formaldehyde 0.25% Triton X-100 3% milk/10% BSA Cy3-donkey anti-rabbit
Other reagents Catalog number Manufacturer
Biotin SP-2001 Vector Laboratories
Protein blocker X0909 Dako, Carpenteria, CA
Avidin–biotin complex PK-6100 Vector Laboratories
Antigen unmasking solution H-3300 Vector Laboratories
SG substrate SK-4700 Vector Laboratories
Nuclear Fast Red H-3403 Vector Laboratories
Diaminobenzidine K3468 Dako
FITC, ﬂuorescein isothiocyanate; HNF4a, hepatocyte nuclear factor 4 a; SMA, smooth muscle actin; SM22, smooth
muscle 22.
aThe antibody concentration for adults was 1:500, the concentration for 1-week-old livers was 1:2250.
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Supplementary Figure 1. Multidimensional scaling plot of
ALGS patients with mild and severe liver disease. ALGS
patients with mild and severe liver disease are plotted on top
of the original 4 HapMap populations. We selected the in-
dividuals inside the boxed region as our cohort of patients
with European ancestry. Utah residents with northern and
western European ancestry (CEU), Japan in Tokyo (JPT), Han
Chinese in Beijing (CHB), and Yoruba in Ibadan, Nigeria (YRI).
Supplemental Figure 2. Q-Q plot of association study. The
observed P values from our variance component model
(black dots) show a good ﬁt to their expected distribution (red
line) and therefore absence of inﬂation owing to population
stratiﬁcation or other forms of bias in the association test.
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